A Multi-center, Randomized Parallel Group, Placebo-Controlled Double-Blind Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Standard Therapy in Pediatric Patients with Systemic Lupus Erythematosus (SLE)
A study for pediatric patients with Systemic Lupus Erythematosus (SLE) using study drug Belimumab
Sponsor: GSK
Enrolling: Male and Female Patients
IRB Number: AAAP7001
U.S. Govt. ID: NCT01649765
Contact: Lourdes Franco: 212-342-3560 / lf2014@cumc.columbia.edu
Additional Study Information: The purpose of the study is to find out if study drug belimumab is safe and effective in treating children with active lupus who are also taking other lupus medicine. Belimumab (also known as BENLYSTA hasbeen approved in the United States, Canada, and Europe for the treatment of adults with active SLEwho are receiving other lupus medicines but not yet approved in children. However, we hope to learnmore about how safe is this drug in children or teenagers and about how well it works.
This study is closed
Lisa Imundo, MD
Do You Qualify?
Does your child have Systemic Lupus Erythematosus (SLE)? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Lourdes Franco